Interestingly, the increased optineurin alone could discriminate T2DM-MCI from T2DM-nMCI; and combination of the elevated optineurin with the activated GSK-3β in platelet enhanced the MCI-discriminating efficiency in T2DM patients [22]. This evidence concerns the gene OPTN and type 2 diabetes mellitus.